Reporting owner · CIK 0001780649

Robins Chad M

Visual SEC Form 4 history across 1 companies, 25 transactions and 5 filings.

CHAIRCEO and ChairmanAdaptive Biotechnologies Corp
Open-market mix
Latest filingAug 20, 2026, 12:15 AM
Filings5Form 4 records
Buying$00 purchases
Selling$25.5M11 sales
Net value−$25.5MBuys minus sells
Companies12 securities
Most recentAug 18, 2026exercise

Open-market buy performance

90-day forward return on this insider's open-market purchases

90d forward
Forward return is not available yet

We compute this from each buy's stock performance 90 days after the transaction. The price history is still being populated for this insider's their open-market buys, so the average and median will appear here once the daily price refresh has covered the relevant trading days.

Monthly open-market activity

Reported purchase and sale transaction counts

Buys Sells
530-3-55Feb 251Jan 261Feb 264Aug 26

Net value flow

Buys minus sells

Feb 25
−$6.4M
Jan 26
−$1.9M
Feb 26
−$2.3M
Aug 26
−$14.9M

Transaction texture

Ownership and ticket size

Average P/S size$2.3M
Median P/S size$1.6M
Direct25
Indirect0
Aug 18, 2026exercise

Filing-only signals

Deterministic matches in this insider's history

Cluster Sellingpattern5Delayed Filingfiling-context3Derivative Transactionfiling-context7Direct Ownershipfiling-context25Large Holdings Reductionholdings4Large Salesize7Repeat Sellerpattern810b5-1 Detectedfiling-context17

Latest Form 4 facts

Quick context from source filings

Latest transaction

sale at Adaptive Biotechnologies Corp on Aug 18, 2026 valued at $5,129.

Review SEC filing
Latest buy

No open-market insider purchase is available.

Latest sale

sale at Adaptive Biotechnologies Corp on Aug 18, 2026 valued at $5,129.

Review SEC filing

Associated companies

Visual map of known reporting history

ADPTAdaptive Biotechnologies Corp25 transactions · latest Aug 20, 2026, 12:15 AM
TickerInsiderRoleTypeSharesValueCodeSignals90d returnFiledTrans date
ADPTROBINS CHAD M
CHAIR
exercise278k$0M
Derivative Transaction Direct Ownership
−4.3%08/2008/18
ADPTROBINS CHAD M
CHAIR
exercise321k$0M
Derivative Transaction Direct Ownership Large Holdings Reduction
−4.3%08/2008/17
ADPTROBINS CHAD M
CHAIR
sale204-$512kS
Cluster Selling Direct Ownership Repeat Seller
−4.3%08/2008/18
ADPTROBINS CHAD M
CHAIR
sale278k-$681MS
Cluster Selling Direct Ownership Large Sale+1
−4.3%08/2008/18
ADPTROBINS CHAD M
CHAIR
exercise278k$182MM
Direct Ownership
−4.3%08/2008/18
ADPTROBINS CHAD M
CHAIR
sale2.52k-$6.45MS
Cluster Selling Direct Ownership Repeat Seller
−4.3%08/2008/17
ADPTROBINS CHAD M
CHAIR
sale318k-$799MS
Cluster Selling Direct Ownership Large Sale
−4.3%08/2008/17
ADPTROBINS CHAD M
CHAIR
exercise321k$210MM
Direct Ownership
−4.3%08/2008/17
ADPTROBINS CHAD M
CHAIR
sale10b5-1124k-$230MS
Direct Ownership Large Sale Repeat Seller+1
−12.4%02/0502/02
ADPTROBINS CHAD M
CHAIR
sale10b5-1124k-$194MS
Cluster Selling Direct Ownership Large Sale+1
—01/0801/05

Robins Chad M Insider Activity FAQ

SEC Form 4 context

Who is Robins Chad M?

Robins Chad M is a reporting owner in SEC Form 4 filings with reporting owner CIK 0001780649.

Which companies has Robins Chad M reported transactions for?

Adaptive Biotechnologies Corp

When was Robins Chad M's latest insider buy?

No open-market insider purchase is available for this period.

When was Robins Chad M's latest insider sale?

sale at Adaptive Biotechnologies Corp on Aug 18, 2026 valued at $5,129.

Where can I see the original SEC filings?

Each transaction row links directly to the source SEC filing so the reported Form 4 details can be reviewed.

Are performance metrics included?

This version does not calculate win rates, forward returns, benchmark-adjusted returns, or high-conviction scores.